SAN FRANCISCO, CALIF.—In the opening presentation of the DES Summit at TCT 2011, Edoardo Camenzind, MD, of the University Hospital of Geneva in Switzerland, a central figure in the series of reports ...
SAN FRANCISCO, CA—The best strategy for treating DES in-stent restenosis is implantation of a different type of DES, according to results of the prospective, multicenter RIBS-III trial. The findings ...
"In a larger cohort of consecutive patients undergoing drug-eluting-stent implantation, we noted a nine-month cumulative stent thrombosis incidence of 1.3%, substantially higher than rates reported in ...
Please provide your email address to receive an email when new articles are posted on . A paclitaxel-eluting balloon showed noninferiority compared with a drug-eluting stent for the treatment of ...
Pittsburgh, PA - Risks associated with the use of a drug-eluting stent (DES) for an "off-label" lesion likely have more to do with patient characteristics than they do with the use of DES, meaning ...
MINNEAPOLIS –– Advancing the clinical practice of interventional cardiovascular medicine, Medtronic Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of the Resolute ...
United States As the healthcare industry reforms to convert the current fee-for-service model to fee-for-value model, intense focus has been placed on the reduction in patient complications, and ...
DUBLIN, Oct. 1, 2020 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results